MedTrace Logo

Study of NGX-1998 for the Treatment of Postherpetic Neuralgia

NCT01228838 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2012-09-10

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of NGX-1998 applied for 5 minutes for the treatment of postherpetic neuralgia (PHN).

Conditions

  • Postherpetic Neuralgia
  • Pain

Interventions

DRUG

NGX-1998

Capsaicin topical liquid to be applied for 5 minutes one time only.

DRUG

Placebo Liquid

Placebo topical liquid to be applied for 5 minutes one time only.

Sponsors & Collaborators

  • NeurogesX

    lead INDUSTRY

Principal Investigators

  • Trudy Vanhove, MD, PhD, MBA · NeurogesX

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01228838 on ClinicalTrials.gov